Cary, N.C. , Jan. 13, 2026 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Sentynl Therapeutics as the exclusive specialty pharmacy provider for ZYCUBO® (formerly known as CUTX-101), a subcutaneous injectable formulation of copper histidinate to treat patients with Menkes disease, a rare and fatal pediatric disease. It is the first FDA-approved treatment for the treatment of Menkes disease in pediatric patients. ZYCUBO is not indicated for the treatment of Occipital Horn Syndrome. In addition, Biologics is the exclusive Hub Services provider and Patient Assistance Program (PAP) Dispensing Pharmacy for ZYCUBO.
For the full prescribing information for ZYCUBO, please click here.
Menkes disease is a rare X-linked recessive pediatric disorder caused by mutations in the ATP7A gene that regulates how your body processes copper. The birth prevalence is believed to be 1 in 34,810 live male births, and potentially as high as 1 in 8,664 live male births with Menkes disease or other ATP7A-related disorders, per year in the U.S.1 Clinical signs are subtle at birth and early infancy until symptoms set in, such as connective tissue issues and severe neurological symptoms, including seizures, hypotonia, failure to thrive, and neurodevelopmental delays. If left untreated, patients usually live fewer than three years.
“Biologics is proud to have been selected by Sentynl as the exclusive provider for ZYCUBO,” says Ela Lourido, vice president and general manager, Biologics by McKesson. “This therapy represents a pivotal milestone for families impacted by Menkes disease, a devastating condition for which there are currently no approved therapeutic options.”
Biologics by McKesson is committed to and recognized for its level of patient support as well as its innovative, high-touch, and multidisciplinary approach. Putting patients first in all they do, the Biologics pharmacy team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various assistance programs.
1. Kaler SG, Ferreira CR, Yam LS. Estimated birth prevalence of Menkes disease and ATP7A-related disorders based on the Genome Aggregation Database (gnomAD). Mol Genet Metab Rep. 2020 Jun 5;24:100602. doi: 10.1016/j.ymgmr.2020.100602.